Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Staphylococcal Skin Infections Clear all
Completed Phase 4 Interventional Results available

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

NCT01126268
View directory record Official record
Conditions
Impetigo, Folliculitis, Secondarily Infected Eczema, Minor Soft Tissue Infections
Interventions
Retapamulin (Altabax)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Months to 98 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Not applicable Interventional

Bleach Bath Treatment of Adults With Atopic Dermatitis

NCT01996150
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
bleach bath (sodium hypochlorite)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

NCT00289588
View directory record Official record
Conditions
Community-Acquired MRSA Infections, Abscesses, Cellulitis, Folliculitis
Interventions
Mupirocin (drug)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
17 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2006 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 4 Interventional

Staph Intervention for Effective Local Defense

NCT06210594
View directory record Official record
Conditions
Staphylococcus Aureus Infection
Interventions
Mupirocin + Nozin + chlorhexidine gluconate, Education + Household supplies
Combination Product · Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 2, 2026, 7:09 AM EDT
Terminated No phase listed Observational

Hidradenitis - an Analysis of Genetic Traits and Linkages in Families

NCT05710393
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
7 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess

NCT02334384
View directory record Official record
Conditions
Furunculosis
Interventions
Antimicrobial TheraGauze
Biological
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Not applicable Interventional Results available

The Natural History of Community-Associated MRSA Infections and Decolonization Strategies

NCT00513799
View directory record Official record
Conditions
Abscesses, Furunculosis, Staphylococcus Aureus, Staphylococcal Skin Infections
Interventions
Mupirocin ointment, Chlorhexidine showers, Bleach baths (dilute), Intensive education on personal hygiene
Drug · Genetic · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 2Phase 3 Interventional

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

NCT01670032
View directory record Official record
Conditions
Impetigo
Interventions
Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID, Placebo Comparator: CD07223 vehicle gel BID, Placebo Comparator: CD07223 vehicle gel TID
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 2, 2026, 7:09 AM EDT
Terminated Phase 2 Interventional Results available

Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults

NCT00869518
View directory record Official record
Conditions
Staphylococcus Aureus, HIV Infections
Interventions
rifabutin plus trimethoprim sulfamethoxazole, placebo plus trimethoprim-sulfamethoxazole
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

NCT00646958
View directory record Official record
Conditions
Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections, Abscess
Interventions
Radezolid, Linezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Montgomery, Alabama • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

NCT02052388
View directory record Official record
Conditions
Skin Infection, Bacterial Infection
Interventions
Daptomycin, Brilacidin
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo

NCT00758862
View directory record Official record
Conditions
Secondarily Infected Traumatic Lesions (SITL), Impetigo
Interventions
2% TD1414 Cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 2, 2026, 7:09 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Skin Immunity Sample Collection Involving Blisters and Biopsies

NCT03921515
View directory record Official record
Conditions
Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)
Interventions
Blister induction, Skin Biopsies
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 2, 2026, 7:09 AM EDT
Not listed Phase 4 Interventional

Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence

NCT02566928
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Recurrence, Staphylococcal Skin Infections, Antibiotic Resistance
Interventions
2% mupirocin ointment, Chlorhexidine wash, Hygiene protocol
Drug · Other · Behavioral
Lead sponsor
Clinical Directors Network
Network
Eligibility
7 Years to 70 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Brooklyn, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 2 Interventional

A Study for Patients With Complicated Skin and Skin Structure Infections

NCT00514527
View directory record Official record
Conditions
Staphylococcal Skin Infections, Wounds and Injuries, Abscess, Cellulitis, Streptococcal Infections
Interventions
oritavancin
Drug
Lead sponsor
Targanta Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
33
States / cities
Mobile, Alabama • Anaheim, California • Buena Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Oct 2, 2026, 7:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ADRN Barrier/Immunoprofiling Exploratory Pilot Study

NCT02115399
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Non-atopic Healthy Controls
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Denver, Colorado • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Not applicable Interventional Results available

Staphylococcus Aureus Decolonization Study

NCT00731783
View directory record Official record
Conditions
Staphylococcal Skin Infections, Abscesses, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions
2% Mupirocin Ointment, 4% Chlorhexidine liquid soap, Hygiene protocol
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months to 21 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Results available

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

NCT01419184
View directory record Official record
Conditions
Staphylococcal Skin Infections
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Mobile, Alabama • Chula Vista, California • Escondido, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

NCT00626795
View directory record Official record
Conditions
Impetigo, Secondarily Infected Traumatic Lesions
Interventions
TD1414 2% cream, Bactroban® (mupirocin) 2% cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
2 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effective Antibiotic Treatment of MRSA

NCT00388310
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Culture
Procedure
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 7:09 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

NCT00730028
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Trimethoprim-sulfamethoxazole, Placebo, Clindamycin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 85 Years
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
San Francisco, California • Torrance, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 2, 2026, 7:09 AM EDT
Completed Phase 4 Interventional

Study of Wound Packing After Superficial Skin Abscess Drainage

NCT00746109
View directory record Official record
Conditions
Abscess, Skin Diseases, Infectious, Boils, Furuncle, Carbuncle, Folliculitis, Cellulitis, Wounds
Interventions
Wound packing, NoPacking
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 24 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2011 · Synced Oct 2, 2026, 7:09 AM EDT